Immix Biopharma Files Proxy Materials
Ticker: IMMX · Form: DEFA14A · Filed: May 21, 2024 · CIK: 1873835
Sentiment: neutral
Topics: proxy-statement, shareholder-communication
TL;DR
Immix Biopharma dropped proxy docs, likely for shareholder votes.
AI Summary
Immix Biopharma, Inc. filed a Definitive Additional Materials (DEFA14A) proxy statement on May 21, 2024. The filing concerns materials related to the company's proxy solicitation, but does not detail specific proposals or financial figures within this document itself. It is a procedural filing related to shareholder communication.
Why It Matters
This filing indicates Immix Biopharma is engaging in shareholder communication, likely related to upcoming votes or corporate actions that require shareholder approval.
Risk Assessment
Risk Level: low — This filing is a procedural proxy statement and does not contain information that directly impacts the company's financial health or stock price.
Key Players & Entities
- Immix Biopharma, Inc. (company) — Registrant
- 0001493152-24-020875 (filing_id) — Accession Number
- 20240521 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' filed by Immix Biopharma, Inc.
Who is the registrant for this filing?
The registrant is Immix Biopharma, Inc.
When was this filing submitted?
The filing was submitted on May 21, 2024.
What is the purpose of a DEFA14A filing?
A DEFA14A filing is used to provide definitive proxy materials to shareholders, often after preliminary materials have been filed, and can include additional soliciting materials.
Does this filing contain specific financial proposals or voting matters?
This particular filing (DEFA14A) is categorized as 'Definitive Additional Materials' and the provided text does not detail specific proposals or financial figures; it serves as a cover and procedural document for proxy materials.
Filing Stats: 126 words · 1 min read · ~1 pages · Grade level 12.7 · Accepted 2024-05-21 16:05:26
Filing Documents
- formdefa14a.htm (DEFA14A) — 16KB
- formdefa14a_001.jpg (GRAPHIC) — 314KB
- formdefa14a_002.jpg (GRAPHIC) — 161KB
- 0001493152-24-020875.txt ( ) — 671KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under § 240.14a-12 IMMIX BIOPHARMA, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11